Elevated Serum Homocysteine Levels Have Differential Gender-Specific Associations with Motor and Cognitive States in Parkinson's Disease.
Journal
Parkinson's disease
ISSN: 2090-8083
Titre abrégé: Parkinsons Dis
Pays: United States
ID NLM: 101539877
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
02
2019
accepted:
23
04
2019
entrez:
6
7
2019
pubmed:
6
7
2019
medline:
6
7
2019
Statut:
epublish
Résumé
Studies attempting to elucidate an association between homocysteine and symptom progression in Parkinson's disease (PD) have had largely discrepant findings. This study aimed to investigate elevated serum homocysteine levels and symptom progression in a cohort of PD patients. Serum homocysteine, folate, and vitamin B12 levels were measured in 205 people with PD and 78 age-matched healthy controls. People with Parkinson's disease underwent a battery of clinical assessments to evaluate symptom severity, including motor (MDS-UPDRS) and cognitive (ACE-R) assessments. Multivariate generalised linear models were created, controlling for confounding variables, and were used to determine whether serum markers are associated with various symptom outcome measures. People with Parkinson's disease displayed significantly elevated homocysteine levels ( Elevated serum homocysteine levels are associated with a greater motor impairment in males with Parkinson's disease and poorer cognitive performance in females with Parkinson's disease. Our gender-specific findings may help to explain previous discrepancies in the literature surrounding the utility of homocysteine as a biomarker in PD.
Sections du résumé
BACKGROUND
BACKGROUND
Studies attempting to elucidate an association between homocysteine and symptom progression in Parkinson's disease (PD) have had largely discrepant findings. This study aimed to investigate elevated serum homocysteine levels and symptom progression in a cohort of PD patients.
METHODS
METHODS
Serum homocysteine, folate, and vitamin B12 levels were measured in 205 people with PD and 78 age-matched healthy controls. People with Parkinson's disease underwent a battery of clinical assessments to evaluate symptom severity, including motor (MDS-UPDRS) and cognitive (ACE-R) assessments. Multivariate generalised linear models were created, controlling for confounding variables, and were used to determine whether serum markers are associated with various symptom outcome measures.
RESULTS
RESULTS
People with Parkinson's disease displayed significantly elevated homocysteine levels (
CONCLUSION
CONCLUSIONS
Elevated serum homocysteine levels are associated with a greater motor impairment in males with Parkinson's disease and poorer cognitive performance in females with Parkinson's disease. Our gender-specific findings may help to explain previous discrepancies in the literature surrounding the utility of homocysteine as a biomarker in PD.
Identifiants
pubmed: 31275543
doi: 10.1155/2019/3124295
pmc: PMC6560330
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3124295Références
Am J Epidemiol. 2000 Jul 15;152(2):140-8
pubmed: 10909951
Metabolism. 1975 Jun;24(6):721-35
pubmed: 1128236
Metabolism. 2001 Dec;50(12):1466-71
pubmed: 11735095
Br J Nutr. 2002 Jan;87(1):71-9
pubmed: 11895315
Mov Disord. 2002 Jul;17(4):682-92
pubmed: 12210857
Neurology. 2002 Nov 12;59(9):1375-80
pubmed: 12427887
Am J Med. 2002 Nov;113(7):537-42
pubmed: 12459398
J Nutr. 2003 Nov;133(11):3630-5
pubmed: 14608086
Neurology. 2003 Dec 9;61(11):1595-9
pubmed: 14663048
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
FEBS Lett. 2006 May 29;580(13):2994-3005
pubmed: 16697371
J Nutr. 2006 Jun;136(6 Suppl):1731S-1740S
pubmed: 16702348
Neurosci Lett. 2006 Aug 14;404(1-2):56-60
pubmed: 16787708
J Alzheimers Dis. 2006 Aug;9(4):393-8
pubmed: 16917147
Int J Geriatr Psychiatry. 2006 Nov;21(11):1078-85
pubmed: 16977673
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
Age Ageing. 2007 Mar;36(2):177-83
pubmed: 17189285
Neurol Res. 2006 Dec;28(8):853-8
pubmed: 17288745
Parkinsonism Relat Disord. 2008;14(4):321-5
pubmed: 18055246
Mov Disord. 2009 Jan 30;24(2):176-82
pubmed: 18951534
Mov Disord. 2009 May 15;24(7):1028-33
pubmed: 19353704
Mov Disord. 2009 Jul 30;24(10):1437-44
pubmed: 19452554
J Nutr. 2010 Mar;140(3):557-64
pubmed: 20071650
N Engl J Med. 1991 Apr 25;324(17):1149-55
pubmed: 2011158
Curr Med Chem. 2010;17(3):213-21
pubmed: 20214564
J Korean Med Sci. 2010 Apr;25(4):509-16
pubmed: 20357989
Ann Neurol. 2010 Jul;68(1):28-36
pubmed: 20582991
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Neural Transm (Vienna). 2011 Sep;118(9):1329-33
pubmed: 21359971
Genet Test Mol Biomarkers. 2012 Jul;16(7):716-21
pubmed: 22385294
Int J Vitam Nutr Res. 2011 Sep;81(5):306-16
pubmed: 22419201
West Afr J Med. 2011 Sep-Oct;30(5):319-24
pubmed: 22752818
Aging Dis. 2013 Mar 07;4(2):57-64
pubmed: 23696950
Arch Gerontol Geriatr. 2013 Nov-Dec;57(3):288-91
pubmed: 23706974
J Geriatr Cardiol. 2014 Mar;11(1):32-8
pubmed: 24748879
J Clin Neurol. 2014 Oct;10(4):281-8
pubmed: 25324876
BMC Neurol. 2014 Nov 30;14:217
pubmed: 25433800
Nutr J. 2015 Jan 10;14:6
pubmed: 25577237
PLoS One. 2015 Feb 18;10(2):e0118686
pubmed: 25692574
Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):287-96
pubmed: 26036286
J Mov Disord. 2015 May;8(2):92-7
pubmed: 26090081
Am J Clin Nutr. 2015 Sep;102(3):529-30
pubmed: 26269372
JAMA Psychiatry. 2016 Jun 1;73(6):606-13
pubmed: 27120188
Parkinsons Dis. 2016;2016:1589747
pubmed: 27642535
Parkinsons Dis. 2016;2016:9539836
pubmed: 27656311
Int J Mol Sci. 2016 Oct 20;17(10):
pubmed: 27775595
Neurosci Lett. 2017 Jan 1;636:190-195
pubmed: 27840145
J Neurol Sci. 2017 Apr 15;375:86-91
pubmed: 28320196
Parkinsonism Relat Disord. 2017 Nov;44:1-5
pubmed: 28807493
Aging Dis. 2018 Feb 1;9(1):51-65
pubmed: 29392081
Mov Disord. 2018 May;33(5):762-770
pubmed: 29508904
Aging Dis. 2018 Jun 1;9(3):523-536
pubmed: 29896439
Aging Dis. 2018 Aug 1;9(4):716-728
pubmed: 30090659
J Biol Chem. 1984 Aug 10;259(15):9508-13
pubmed: 6746658
J Intern Med. 1994 Dec;236(6):633-41
pubmed: 7989898
Arch Neurol. 1998 Nov;55(11):1449-55
pubmed: 9823829